DHTRF (DRI Healthcare Trust) Moat Score: 4/10 (As of Jul. 04, 2026)


DHTRF DRI Healthcare Trust DHTRF
33 GF Score
Price $12.70
GF Value $13.28
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is DRI Healthcare Trust Moat Score?

DRI Healthcare Trust DHTRF 33 Moat Score is 4 as of Jul. 04, 2026. GuruFocus rates DHTRF with a GF Score™ of 33/100 and a GF Value™ of $13.28 (Fairly Valued). The stock has 4 warning signs investors should review. Among 1,032 Drug Manufacturers companies, DRI Healthcare Trust ranks better than 90.7% on this metric.

DRI Healthcare Trust has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

DRI Healthcare Trust has Narrow Moat: DRI Healthcare Trust has a discernible but modest moat due to its specialized focus on healthcare royalties, providing some market leadership and unique intellectual property. However, it lacks strong brand strength and significant customer switching costs.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes DRI Healthcare Trust might have Narrow Moat - Discernible but modest moat.

DRI Healthcare Trust  (OTCPK:DHTRF) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

DRI Healthcare Trust Moat Score Related Terms

DHTRF vs ZTS, UTHR: Moat Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, DRI Healthcare Trust's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

DRI Healthcare Trust Moat Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, DRI Healthcare Trust's Moat Score distribution charts can be found below:

* The bar in red indicates where DRI Healthcare Trust's Moat Score falls into.


DHTRF
33GF Score
DRI Healthcare Trust DHTRF
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 4 mean?
DRI Healthcare Trust (DHTRF) has a Moat Score of 4 as of Jul. 04, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, DRI Healthcare Trust ranks #96 out of 1032 companies in the Drug Manufacturers industry, placing it in the top 9.3%.
Is DRI Healthcare Trust's Moat Score too high?
DRI Healthcare Trust's current Moat Score is 4. Based on the distribution chart, DRI Healthcare Trust ranks #96 out of 1032 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, DRI Healthcare Trust has a GF Score™ of 33/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does DRI Healthcare Trust's Moat Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, DRI Healthcare Trust ranks #96 out of 1032 companies for Moat Score. This places DRI Healthcare Trust in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Drug Manufacturers company?
A good Moat Score depends on the Drug Manufacturers industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. DRI Healthcare Trust's current Moat Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DRI Healthcare Trust stock overvalued right now?
Based on GuruFocus' analysis, DRI Healthcare Trust (DHTRF) is currently considered Fairly Valued. The stock's GF Value™ is $13.28, compared to a current price of $12.70 — trading 4.4% below its estimated fair value. The current Moat Score is 4. DRI Healthcare Trust's overall GF Score™ is 33/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For DRI Healthcare Trust (DHTRF), the current Moat Score is 4 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is DRI Healthcare Trust (DHTRF) Overvalued in 2026?

Based on GuruFocus' analysis, DRI Healthcare Trust stock appears to be undervalued. The current stock price of $12.70 is trading 4.4% below its estimated GF Value™ of $13.28. GuruFocus considers DRI Healthcare Trust to be Fairly Valued.

Key valuation signals for DHTRF:

  • Moat Score: 4
  • GF Value™: $13.28 vs. price of $12.70 (4.4% below fair value)
  • GF Score™: 33/100 with 4 warning signs

No single metric tells the full story. See the DHTRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

DRI Healthcare Trust Business Description

Other Exchanges DHT.UN:CanadaDHT.U:Canada
Address 100 King Street West, 1 First Canadian Place, Suite 6200, Toronto, ON, CAN, M5X 1B8
DRI Healthcare Trust is an open-ended trust that purchases royalty entitlements on products that address unmet medical needs, providing its unitholders with top-line exposure to a portfolio of therapeutics. Its portfolio comprises several royalty streams on products that treat conditions in a number of therapeutic areas, including oncology, neurology, ophthalmology, endocrinology, hematology, dermatology, as well as lysosomal storage disorders (LSD) and immunology. The Trust has concluded that it operates as one segment, focused on acquiring royalty assets. Geographically, it generates maximum royalty income from the sale of products underlying its royalty agreements in the United States, followed by other markets such as Japan, the European Union, and the rest of the world.
33GF Score

Get the complete analysis for DHTRF

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.70
Price
$13.28
GF Value